Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nuformix Plc ( (GB:NFX) ) has issued an announcement.
Nuformix plc, a company specializing in drug repurposing for fibrosis and oncology, announced the posting of its Annual Financial Report for the year ending September 2024, along with the notice for its 2025 Annual General Meeting. The AGM is scheduled for March 20, 2025, and this release underscores Nuformix’s ongoing commitment to transparency and stakeholder engagement as it continues to explore early licensing opportunities in its preclinical asset pipeline.
More about Nuformix Plc
Nuformix is a pharmaceutical development company that focuses on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company specializes in discovering, developing, and patenting novel drug forms with improved physical properties, aiming to create new products for new indications that are distinct from the original in terms of dosage, delivery route, or presentation, thereby opening up new commercial opportunities.
YTD Price Performance: 100.0%
Average Trading Volume: 70,578,358
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.67M
Find detailed analytics on NFX stock on TipRanks’ Stock Analysis page.
